Drugs / fb-PMT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05226494 | Jun 2022 → Oct 2026 expected | malignant glioma | NanoPharmaceuticals LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fb-PMT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05226494 ↗ |
| Route | Subcutaneous | “Daily subcutaneous injection of fb-PMT” NCT05226494 ↗ |